RPRX

Royalty Pharma plc NMS · RPRX

$57.69 +0.40 (+0.70%)

Neutral · +0.78σ

+ Compare Open in Sniper

Mkt cap $33.2B

P/E 30.4

Day $56.90 – $57.78

52wk $39.02 – $59.44

Avg vol 3.8M

Beta 0.42

Div yld 1.64%

Next earnings 2026-08-05

Quick read

Plain English

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

RPRX last traded at $57.69, up 0.7% on the day; that's in the upper part of its 52-week range ($39.02–$59.44). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, +0.75 ATR from EMA21 — no notable pattern

Long —

score 12 · tech 12 / 80 · support 0 / 20

above KC1 lower, +0.75 ATR from EMA21 · no notable pattern

· Aligned with weak uptrend

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 12 · tech 12 / 80 · support 0 / 20

below KC1 upper, +0.75 ATR from EMA21 · no notable pattern

· Stochastic bear cross

How this grade was earned

total 12 pts

Cycle position 6

Momentum 3

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Fair-value range

$16.10 – $34.20

Verdict

Unknown

Accounting quality Weak

✓ Current ratio 2.40 (antifragile)
✓ Goodwill 5% of assets (organic growth)
✓ Positive retained earnings
✓ Gross margin 115% (pricing power)

⚠ Debt exceeds cash
⚠ Stock comp 12% of revenue (heavy dilution)

Key statistics

All statistics →

RPRX is a $33.2 billion company, priced at 30× last year's earnings, and it moves more calmly than the market (beta 0.4); the stock is trading near the top of its 52-week range.

Mkt cap $33.2B

P/E ttm 30.4

Fwd P/E 10.3

Beta 0.42

Day range $56.90 – $57.78

52w range $39.02 – $59.44

Avg vol 3.8M

RSI(2) 55.9

ROE 13.8%

Net mgn 33.9%

FCF mgn -40.2%

Debt/Eq 0.90

Div yld 1.64%

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-05

52-week range · today's price

$39.02$59.44

More on RPRX

Options idea

See more →

CALL $58 2026-08-21

$2.50

PUT $58 2026-08-21

$2.65

Earnings

See more →

Last reported: 2026-05-06
EPS (act / est): 1.30 / 1.18
Surprise: +9.4%
Next report: 2026-08-05

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, he…